Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521781 · ClinicalTrials.gov registry record · Phase 2
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00521781 is a Phase 2 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 14 participants.
The verdict
NCT00521781, a Phase 2 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of the clinical trial is to assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic adenocarcinoma of the prostate, as well as to assess safety and tolerability of the study drug regimen and to evaluate secondary efficacy endpoints such as overall survival and duration of response.
Interventions
- DRUG Bicalutamide
- DRUG Abraxane
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521781
The ClinicalTrials.gov registry entry for NCT00521781 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bicalutamide is the first listed.
NCT00521781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00521781 about?
NCT00521781 is a clinical study titled "Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer". The purpose of the clinical trial is to assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic adenocarcinoma of the prostate, as well as to assess safety and tolerability of...
What is the current status of trial NCT00521781?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00521781?
The interventions under investigation include: Bicalutamide (DRUG), Abraxane (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT00521781?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.